Pre-treatment has been extended to some patients who are already in the hospital

Ronaprev, treatment for it Kovid-19 Synthetic antibodies, which until then had been specialized for the prevention of the disease and the fight against its early forms, were also authorized on Friday in France‌ in a more advanced stage in patients already hospitalized. “By September 3, 2021, we are expanding the use of dual monoclonal antibody therapy kasirivimab / imdevimab, depending on the identified medical need for the management of patients in the advanced stage of Kovid-19 disease,” the press release said. National Medicines Safety Agency (ANSM).

This treatment, marketed under the name Ronaprev by the American laboratory Regeneran, is already authorized to protect against early forms of the disease in high-risk individuals and to prevent them from appearing immunocompromised. It is now given in more advanced stages, in patients already hospitalized and at risk of developing a severe form. “This applies to patients who are not immunocompromised, at risk for complications related to comorbidities, patients aged 80 and over,” ANSM explained.